Top-Rated StocksTop-RatedNASDAQ:DXCM DexCom (DXCM) Stock Forecast, Price & News $119.71 -5.67 (-4.52%) (As of 06/7/2023 ET) Add Compare Share Share Today's Range$117.74▼$126.1950-Day Range$112.47▼$125.3852-Week Range$67.11▼$126.59Volume3.10 million shsAverage Volume2.45 million shsMarket Capitalization$46.40 billionP/E Ratio171.02Dividend YieldN/APrice Target$126.81 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability DexCom MarketRank™ ForecastAnalyst RatingModerate Buy2.92 Rating ScoreUpside/Downside5.9% Upside$126.81 Price TargetShort InterestBearish3.73% of Shares Sold ShortDividend StrengthN/ASustainability-0.76Upright™ Environmental ScoreNews Sentiment0.36Based on 7 Articles This WeekInsider TradingSelling Shares$10.11 M Sold Last QuarterProj. Earnings Growth38.68%From $1.06 to $1.47 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.92 out of 5 starsMedical Sector606th out of 981 stocksSurgical & Medical Instruments Industry59th out of 97 stocks 1.5 Analyst's Opinion Consensus RatingDexCom has received a consensus rating of Buy. The company's average rating score is 2.92, and is based on 10 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $126.81, DexCom has a forecasted upside of 5.9% from its current price of $119.71.Amount of Analyst CoverageDexCom has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.73% of the outstanding shares of DexCom have been sold short.Short Interest Ratio / Days to CoverDexCom has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in DexCom has recently increased by 13.59%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldDexCom does not currently pay a dividend.Dividend GrowthDexCom does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreDexCom has received a 75.05% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Continuous glucose monitoring systems" and "Blood glucose monitors" products. See details.Environmental SustainabilityThe Environmental Impact score for DexCom is -0.76. Previous Next 1.9 News and Social Media Coverage News SentimentDexCom has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for DexCom this week, compared to 8 articles on an average week.Search InterestOnly 27 people have searched for DXCM on MarketBeat in the last 30 days. This is a decrease of -23% compared to the previous 30 days.MarketBeat Follows23 people have added DexCom to their MarketBeat watchlist in the last 30 days. This is an increase of 109% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DexCom insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,107,329.00 in company stock.Percentage Held by InsidersOnly 0.41% of the stock of DexCom is held by insiders.Percentage Held by Institutions94.01% of the stock of DexCom is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for DexCom are expected to grow by 38.68% in the coming year, from $1.06 to $1.47 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DexCom is 171.02, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 145.50.Price to Earnings Ratio vs. SectorThe P/E ratio of DexCom is 171.02, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 145.72.Price to Book Value per Share RatioDexCom has a P/B Ratio of 21.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About DexCom (NASDAQ:DXCM) StockDexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.Read More Receive DXCM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter. Email Address DXCM Stock News HeadlinesJune 5, 2023 | msn.comIf You Invested $100 In This Stock 15 Years Ago, You Would Have $6,800 TodayJune 4, 2023 | finance.yahoo.comDow Jones Futures: Character Change For Market; Oil Prices Jump On Saudi Output CutJune 8, 2023 | UNKNOWN (Ad)This NASDAQ Stock Is The Amazon Of Medical SupplyThis Little Known Company IS Quickly Becoming The Amazon Of Medical Supply. Learn More NowJune 4, 2023 | finance.yahoo.comDow Jones Futures: Market Rally Shows Character Change; Tesla, Apple In FocusJune 1, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Dr Reddy’s Laboratories (RDY), Dexcom (DXCM)May 31, 2023 | marketwatch.comDexCom Inc. stock outperforms market on strong trading dayMay 31, 2023 | wsj.comDexCom Inc.May 31, 2023 | finance.yahoo.com3 Stock-Split Stocks Billionaires Can't Stop BuyingJune 8, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.May 30, 2023 | nasdaq.comLLY, DXCM, or ISRG: Which Healthcare Stock is the Top Stock Pick?May 25, 2023 | msn.comDexCom Unusual Options ActivityMay 25, 2023 | fxstreet.comIs DexCom a go-to health care stock? [Video]May 25, 2023 | americanbankingnews.comSteven Robert Pacelli Sells 412 Shares of DexCom, Inc. (NASDAQ:DXCM) StockMay 25, 2023 | seekingalpha.comDexCom: 120 Times Free Cash Flow Is Still UnreasonableMay 24, 2023 | msn.comDexCom: Growth Should Accelerate From HereMay 24, 2023 | americanbankingnews.comDexCom, Inc. (NASDAQ:DXCM) CFO Jereme M. Sylvain Sells 2,400 SharesMay 23, 2023 | fool.comDexCom (NASDAQ: DXCM)May 23, 2023 | finance.yahoo.comInvesting $1,000 in These 2 Top Growth Stocks Would Be a Brilliant MoveMay 22, 2023 | americanbankingnews.comDexCom, Inc. (NASDAQ:DXCM) Receives $126.81 Average PT from BrokeragesMay 19, 2023 | benzinga.comHere's How Much You Would Have Made Owning DexCom Stock In The Last 5 YearsMay 17, 2023 | finance.yahoo.comWhat Recession? These Companies Expect 20% Sales Growth This Year.May 16, 2023 | finance.yahoo.comZacks Investment Ideas feature highlights: Dexcom, Rambus, Advanced Micro Devices, Nvidia and VipshopsMay 16, 2023 | americanbankingnews.comDexCom, Inc. (NASDAQ:DXCM) Expected to Post Q2 2023 Earnings of $0.20 Per ShareMay 15, 2023 | finance.yahoo.com3 Stocks on the Verge of Breaking OutMay 12, 2023 | msn.comHow Is The Market Feeling About DexCom?May 12, 2023 | msn.comCheck Out What Whales Are Doing With DXCMMay 11, 2023 | businesswire.comDexcom Showcases Accuracy, Reliability and Ease of Use of Its Dexcom G6 CGM System at the 66 th Annual Meeting of the Japan Diabetes SocietySee More Headlines DXCM Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DXCM Company Calendar Last Earnings4/27/2023Today6/07/2023Next Earnings (Estimated)7/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:DXCM CUSIP25213110 CIK1093557 Webwww.dexcom.com Phone(858) 200-0200Fax858-200-0201Employees7,600Year Founded1999Price Target and Rating Average Stock Price Forecast$126.81 High Stock Price Forecast$150.00 Low Stock Price Forecast$105.00 Forecasted Upside/Downside+5.9%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)$0.70 Trailing P/E Ratio171.02 Forward P/E Ratio112.93 P/E GrowthN/ANet Income$341.20 million Net Margins9.68% Pretax Margin13.87% Return on Equity18.29% Return on Assets7.35% Debt Debt-to-Equity Ratio0.54 Current Ratio2.02 Quick Ratio1.82 Sales & Book Value Annual Sales$2.91 billion Price / Sales15.95 Cash Flow$1.26 per share Price / Cash Flow95.18 Book Value$5.52 per share Price / Book21.69Miscellaneous Outstanding Shares387,640,000Free Float386,047,000Market Cap$46.40 billion OptionableOptionable Beta1.15 Social Links Key ExecutivesKevin Ronald SayerChairman, President & Chief Executive OfficerJacob S. LeachChief Operating Officer & Executive Vice PresidentJereme M SylvainChief Financial Officer & EVP-FinanceAndrew K. BaloEVP-Global Medical Affairs, Access & EvidenceShelly R. SelvarajChief Information Officer & Senior Vice PresidentKey CompetitorsResMedNYSE:RMDBoston ScientificNYSE:BSXBecton, Dickinson andNYSE:BDXBaxter InternationalNYSE:BAXInsuletNASDAQ:PODDView All CompetitorsInsiders & InstitutionsEP Wealth Advisors LLCBought 11,274 shares on 6/5/2023Ownership: 0.003%Prelude Capital Management LLCSold 9,787 shares on 6/1/2023Ownership: 0.001%ProShare Advisors LLCBought 49,391 shares on 5/26/2023Ownership: 0.103%Steven Robert PacelliSold 412 sharesTotal: $48,883.80 ($118.65/share)Toroso Investments LLCBought 423 shares on 5/23/2023Ownership: 0.003%View All Insider TransactionsView All Institutional Transactions DXCM Stock - Frequently Asked Questions Should I buy or sell DexCom stock right now? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last twelve months. There are currently 2 hold ratings, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" DXCM shares. View DXCM analyst ratings or view top-rated stocks. What is DexCom's stock price forecast for 2023? 13 Wall Street analysts have issued 1-year price targets for DexCom's shares. Their DXCM share price forecasts range from $105.00 to $150.00. On average, they expect the company's share price to reach $126.81 in the next year. This suggests a possible upside of 5.9% from the stock's current price. View analysts price targets for DXCM or view top-rated stocks among Wall Street analysts. How have DXCM shares performed in 2023? DexCom's stock was trading at $113.24 at the start of the year. Since then, DXCM stock has increased by 5.7% and is now trading at $119.71. View the best growth stocks for 2023 here. When is DexCom's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, July 27th 2023. View our DXCM earnings forecast. How were DexCom's earnings last quarter? DexCom, Inc. (NASDAQ:DXCM) posted its quarterly earnings results on Thursday, April, 27th. The medical device company reported $0.17 EPS for the quarter, topping analysts' consensus estimates of $0.15 by $0.02. The medical device company earned $7.45 billion during the quarter, compared to the consensus estimate of $720.52 million. DexCom had a trailing twelve-month return on equity of 18.29% and a net margin of 9.68%. The company's quarterly revenue was up 1085.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.08 EPS. Read the conference call transcript. What ETFs hold DexCom's stock? ETFs with the largest weight of DexCom (NASDAQ:DXCM) stock in their portfolio include First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Global X Internet of Things Thematic ETF (SNSR), ProShares Nasdaq-100 Dorsey Wright Momentum ETF (QQQA), Global X Telemedicine & Digital Health ETF (EDOC), American Century Mid Cap Growth Impact (MID), Simplify Health Care ETF (PINK), Fidelity Digital Health ETF (FDHT) and Neuberger Berman Disrupters ETF (NBDS). When did DexCom's stock split? DexCom shares split on Friday, June 10th 2022. The 4-1 split was announced on Friday, March 25th 2022. The newly minted shares were distributed to shareholders after the closing bell on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split. What guidance has DexCom issued on next quarter's earnings? DexCom issued an update on its FY 2023 earnings guidance on Thursday, April, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $3.40 billion-$3.52 billion, compared to the consensus revenue estimate of $3.47 billion. What is Kevin Sayer's approval rating as DexCom's CEO? 347 employees have rated DexCom Chief Executive Officer Kevin Sayer on Glassdoor.com. Kevin Sayer has an approval rating of 88% among the company's employees. What other stocks do shareholders of DexCom own? Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), Salesforce (CRM), ServiceNow (NOW), Walt Disney (DIS), Trade Desk (TTD) and Shopify (SHOP). What is DexCom's stock symbol? DexCom trades on the NASDAQ under the ticker symbol "DXCM." Who are DexCom's major shareholders? DexCom's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (4.43%), Sands Capital Management LLC (3.54%), Geode Capital Management LLC (2.14%), Jennison Associates LLC (1.87%), Bank of New York Mellon Corp (1.29%) and Blair William & Co. IL (1.12%). Insiders that own company stock include Andrew K Balo, Andrew K Balo, Barbara Kahn, Barry J Regan, Bridgette P Heller, Chad Patterson, Jacob Steven Leach, Jay S Skyler, Jereme M Sylvain, Jereme M Sylvain, Kevin R Sayer, Kevin R Sayer, Mark G Foletta, Matthew Vincent Dolan, Michael Jon Brown, Nicholas Augustinos, Patrick Michael Murphy, Paul R Flynn, Paul R Flynn, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Sadie Stern, Shelly Ramasamy Selvaraj, Steven R Altman, Steven Robert Pacelli and Sumi Shrishrimal. View institutional ownership trends. How do I buy shares of DexCom? Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is DexCom's stock price today? One share of DXCM stock can currently be purchased for approximately $119.71. How much money does DexCom make? DexCom (NASDAQ:DXCM) has a market capitalization of $46.40 billion and generates $2.91 billion in revenue each year. The medical device company earns $341.20 million in net income (profit) each year or $0.70 on an earnings per share basis. How many employees does DexCom have? The company employs 7,600 workers across the globe. Does DexCom have any subsidiaries? The following companies are subsidiares of DexCom: DexCapital LLC, DexCom (Canada) Inc., DexCom (UK) Distribution Ltd., DexCom (UK) Intermediate Holdings Ltd., DexCom (UK) Ltd., DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom Deutschland GmbH, DexCom International Ltd., DexCom Kommanditbolag, DexCom Operating Ltd., DexCom Philippines Inc, DexCom Suisse GmbH, Nintamed Handels GmbH, SweetSpot Diabetes Care Inc, The Glucose Program LLC, and TypeZero Technologies Inc.Read More How can I contact DexCom? DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The official website for the company is www.dexcom.com. The medical device company can be reached via phone at (858) 200-0200, via email at investorrelations@dexcom.com, or via fax at 858-200-0201. This page (NASDAQ:DXCM) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DexCom, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.